Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat

Moderna on track to report late-stage COVID-19 vaccine data next month

October 29, 2020 7:26 AM EDT

By Manas Mishra and Carl O'Donnell

(Reuters) - Moderna Inc (NASDAQ: MRNA) on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the clearest timeline yet for when the world will know whether it is effective.

The company, one of the front-runners in the global race to produce vaccines to protect against COVID-19, said an independent data monitoring committee is expected to conduct an interim review of its ongoing 30,000-person trial in November. Its shares rose 3%.

The... More

Next crop of COVID-19 vaccine developers take more traditional route

October 29, 2020 12:10 AM EDT

By Julie Steenhuysen and Caroline Copley

CHICAGO/BERLIN (Reuters) - The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.

The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop.

Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed. They include messenger RNA... More

Fauci Says Vaccine Won't Be Available Until Jan. at Earliest - Bloomberg, Citing Comments at JAMA

October 28, 2020 3:52 PM EDT

Fauci Says Vaccine Won't Be Available Until Jan. at Earliest - Bloomberg, Citing Comments at JAMA

... More

COVID Vaccine Data Delayed Amid Less Infection Among Trial Participants, But Data Still Expected Next Month - Morgan Stanley

October 28, 2020 10:28 AM EDT

Morgan Stanley biotech analyst Matthew Harrison weighed in on the COVID-19 vaccine situation as timelines are drawn-out. Harrison believes COVID infections are lower in vaccine trial participants compared to the local populations at the clinical sites, which delays the initial interim analyses. That said, the firm still sees clear trial data in November.

"We now assume trial infection rates are 50% lower than the general... More

Stocks with Implied Volatility Movement

October 28, 2020 3:26 AM EDT

Moderna (NASDAQ: MRNA) volatility index movement increasing vs. 30D HV

... More

Moderna (MRNA) Announces UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of mRNA Vaccine Against COVID-19

October 27, 2020 9:02 AM EDT

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Medicines and Healthcare... More

Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

October 27, 2020 6:51 AM EDT

By Michael Erman and Manas Mishra

(Reuters) - Drugmaker Pfizer Inc (NYSE: PFE) said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer said there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.

... More